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Summary. We propose a hierarchical model for the probability of dose-limiting toxicity (DLT) for combinations of doses of
two therapeutic agents. We apply this model to an adaptive Bayesian trial algorithm whose goal is to identify combinations
with DLT rates close to a prespecified target rate. We describe methods for generating prior distributions for the parameters
in our model from a basic set of information elicited from clinical investigators. We survey the performance of our algorithm
in a series of simulations of a hypothetical trial that examines combinations of four doses of two agents. We also compare
the performance of our approach to two existing methods and assess the sensitivity of our approach to the chosen prior
distribution.
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1. Background and Significance
Phase I trials of combination cancer therapies have been
published for a variety of cancer types, including small-cell
lung cancer (Rudin et al., 2004), gastric cancer (Inokuchi
et al., 2006), melanoma (Azzabi et al., 2005), ovarian can-
cer (Benepal et al., 2005), and renal cell carcinoma (Amato,
Morgan, and Rawat, 2006). Unfortunately, all of these trials,
and many others similar to them, suffer from poor study de-
signs that have two distinct limitations. The first limitation
is that four of five of the cited trials escalated doses of only
one of the agents, while fixing the dose of the other agent at
some pre-determined dose. However, it is very possible that
the safest dose of each agent will depend upon which dose of
the other agent is used. In an ideal design, simultaneous mod-
ification of doses for both agents will be possible. The second
limitation is that the cited trials used a variant of the so-called
3+3 design (Storer, 1989), which has been shown to have poor
operating characteristics, including a strong propensity to se-
lect doses below the actual maximum tolerated dose (Ahn,
1998; Lin and Shih, 2001). A preferred design would incorpo-
rate a parametric model describing how doses of both agents
contribute to the probability of dose-limiting toxicity (DLT).
Research into parametric models for two-agent combina-
tions has been ongoing for over 40 years, starting with the
work of Plackett and Hewlett (1967). However, this research
was primarily theoretic and was not specifically motivated by
dose-finding studies. In the past decade, a handful of dual-
agent Phase I study designs have been published. Kramar,
Lebecq, and Candalh (1999) first noted the limitations of an
algorithmic approach and instead employed the maximum-
likelihood version (O’Quigley and Shen, 1996) of the con-
tinual reassessment method (CRM) of O’Quigley, Pepe, and
Fisher (1990). However, as the CRM is an adaptive design for
single-agent Phase I trials, Kramar and colleagues (1999) then
developed an ad-hoc formula allowing them to combine a dose
of each agent into a single imputed dose in an effort to provide
an ordering for the various dose combinations under study.
A related approach was proposed by Conaway, Dunbar, and
Peddada (2004), in which the ordering restrictions were more
formally incorporated into parameter estimation and selec-
tion of the optimal combination. A very recent CRM-based
design was proposed by Yuan and Yin (2008).
Two model-based, adaptive approaches that reflect the in-
dividual contributions of both agents also exist. Thall et al.
(2003) proposed a design that identifies an entire “contour” of
combinations by modeling the probability of DLT as a func-
tion of both doses using a six-parameter logistic regression
model. One unique aspect of Thall et al. (2003) is that the
design first studies specific combinations of two agents, and at
the occurrence of the first DLT, the study is widened to exam-
ine a continuum of doses in a neighborhood of the combination
in which the first DLT occurred. An alternate two-stage design
was developed by Wang and Ivanova (2005), in which the first
stage is viewed as a “start-up” for the study when little data
are available for parameter estimation. Once the first stage
has developed, a sufficient toxicity profile of the combinations
using algorithmic approaches, those combinations deemed
“acceptable” in the first stage are more fully examined with
adaptive, Bayesian approaches applied to their proposed para-
metric model. The design of Wang and Ivanova (2005) desig-
nates one agent as primary (referred to as “dose 1”) and seeks
one suitable dose of the secondary agent for every dose of the
primary agent that leads to acceptable DLT rates.
In this article, we propose another approach that has dis-
tinct differences from the designs of Thall et al. (2003) and
Wang and Ivanova (2005). First, patients will be enrolled con-
tinuously in a single stage, with the parametric model and
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corresponding Bayesian methods applied throughout the
study. To limit the selected prior distribution’s influence early
in the study, we will implement a stopping rule based solely
upon the cumulative number of DLTs observed in the study.
Second, in an approach novel to dose-finding study designs,
our design does not assume that the probability of DLT is a
fixed quantity for every subject receiving the same combina-
tion and we choose to model the effects of each agent on the
parameters describing the distribution of DLT probabilities
for each combination. As a result, our design will accommo-
date subject heterogeneity better than the competing designs
that assume that the probability of DLT is constant for each
combination. In Section 2, we describe our hierarchical model
and the resulting likelihood, and in Section 3, we describe
how to use elicited clinical information to develop appropri-
ate prior distributions for each model parameter. Section 4
outlines the design and conduct of an actual trial, and Sec-
tion 5 numerically examines the performance of our design in
a variety of settings, and includes a direct comparison to the
CRM and method of Wang and Ivanova (2005). We conclude
with summarizing remarks in Section 6.
2. Proposed Hierarchical Model
We have a Phase I study designed to examine combinations
of m doses of Agent A, denoted a1 < a2 < · · · < am , and n
doses of Agent B, denoted b1 < b2 < · · · < bn . Let (j, k) rep-
resent the combination of dose aj , j = 1, 2, . . . , m, and dose
bk , k = 1, 2, . . . , n. Note that the value ascribed to each aj
and bk will not be the actual clinical values of the doses, but
will be “effective” dose values that will lend stability to our
dose-toxicity model, an approach used in numerous Phase I
trial designs. We will describe how to determine reasonable
effective dose values in Section 3.
We let pjk denote the probability of a DLT for a subject
receiving combination (j, k), and we let p∗ denote the desired
DLT rate of the optimal combination. Thus, the combination
(j, k) whose corresponding probability of DLT is closest to
p∗ should be selected as the maximum tolerated combination
(MTC); we denote this combination as (j∗, k∗). We will as-
sume that each pjk has a beta distribution with parameters
αjk and βjk , which is a useful probability model for our set-
ting because αjk (βjk ) can be interpreted as the prior number
of subjects assigned to combination (j, k) expected to have
(not have) a DLT. It is also natural to incorporate variability
into the DLT rates of each combination as dose-finding stud-
ies tend to enroll very heterogeneous samples of subjects. As
we would expect αjk (βjk ) to increase (decrease) with both aj
and bk , we explicitly model αjk and βjk with the following
parametric functions of aj and bk :
log{αjk (θ)} = θ0 + θ1aj + θ2bk (1)
log{βjk (φ)} = φ0 − φ1aj − φ2bk , (2)
in which θ = {θ0, θ1, θ2} has a multivariate normal distribu-
tion with mean μ = {μ0, μ1, μ2}, φ = {φ0, φ1, φ2} has a multi-
variate normal distribution with mean ω = {ω0, ω1, ω2}, and
both θ and φ have variance σ2I3, in which I3 is a 3 × 3 identity
matrix.
We have chosen to omit the interactive effects of doses. This
decision is based, in part, on the work of Wang and Ivanova
(2005), who found that the no interaction version of their
model performed better than the interaction version, at least
in the settings examined. Furthermore, we do not seek to cor-
rectly model the entire dose–response curve for every combi-
nation, but only those in a neighborhood of the actual MTC,
and it has been documented that underparameterized models
can provide adequate local fit sufficient for dose-finding stud-
ies (O’Quigley and Paoletti, 2003). Nonetheless, our model
could be easily generalized to include an interaction term in
each of equations (1) and (2), although additional parame-
ters will necessarily increase the sample size required for the
study. We have also assumed that all six regression parameters
are independent and have the same prior variance σ2; either
assumption could be relaxed by incorporating additional vari-
ance and/or covariance parameters. However, we have found
in simulations (results not shown) that additional parame-
ters add needless complexity to the model with little gain in
algorithm performance.
Let Njk denote the number of subjects assigned to combi-
nation (j, k), of whom Yjk subjects have experienced a DLT. If
we then define Y = {Yjk : j = 1, 2, . . . , m; k = 1, 2, . . . n} and
N = {Njk : j = 1, 2, . . . , m; k = 1, 2, . . . n}, the posterior dis-
tribution for (θ, φ) is
















fj k (Yjk | θ, φ, Njk )g(θ)h(φ)dθdφ
where g(·) and h(·) are the respective multivariate normal
priors for θ and φ described earlier. Although a closed-form
expression for the posterior distribution is not available, sam-
ples from the posterior distribution are easily obtained using
Markov chain Monte Carlo (MCMC) methods (Robert and
Casella, 1999). These samples lead to posterior distributions
for each element of θ and φ, which, in turn, lead to a pos-
terior distribution for each pjk . The corresponding posterior
means, p̄j k , will then be used to determine which combination
is deemed the current estimate of the MTC as more formally
explained in Section 4.
3. Developing Priors and Effective Dose Values
In order to identify appropriate hyperparameter and effec-
tive dose values, we need the investigator to supply p̃j 1 and
p̃1k , the respective a priori values for E{pj 1} and E{p1k }, for
j = 1, 2, . . . , m and k = 1, 2, . . . , n. Thus, at a minimum, we
expect the investigator to have sufficient historical informa-
tion regarding the toxicity profiles of the doses of both agents
when combined with the lowest dose of the other agent. To
simplify computation, we set the lowest dose of each agent to
zero (a1 = b1 = 0). As a result, log(α11) = θ0 and log(β11) = φ0
so that θ0 and φ0 describe the expected numbers of DLTs for
the combination using the lowest dose of each agent, and the
remaining parameters in equations (1) and (2) will describe
how the expected numbers of DLTs for the other combinations
differ from combination (1, 1).
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leading to the solutions μ0 = log(Kp̃11) and ω0 = log(K [1 −
p̃11]), where K = 1000 was chosen as a scaling factor to keep
both hyperparameters sufficiently above zero. We have se-
lected normal priors for our regression parameters, and have
therefore allowed for the possibility of a decreased probability
of DLT with increasing doses of either agent, although we do
expect there to be low probability of such an occurrence. As a
result, we have selected the values μ1 = μ2 = ω1 = ω2 = 2
√
σ2
so that 97.5% of the prior distributions for θ1, θ2, φ1, and φ2
will lie above zero, depending upon the value of σ2.
Given these values, we define the elicited odds ratios
ÕRj. = exp
{
p̃j 1/[1 − p̃j 1]
p̃11/[1 − p̃11]
}
= exp{(θ1 + φ1)aj }




p̃1k /[1 − p̃1k ]
p̃11/[1 − p̃11]
}
= exp{(θ2 + φ2)bk }
≈ exp{(μ2 + ω2)bk }.
As a result, our effective dose values are aj = (μ1 + ω1)−1
log(ÕRj. ) and bk = (μ2 + ω2)−1log(ÕR.k ), meaning all doses
are rescaled to be proportional to log-odds ratios relative
to combination (1,1). Because the elicited probabilities of
toxicity will increase with an increase in the dose of either
Agent A or Agent B, we will have a1 < a2 < · · · < am and
b1 < b2 < · · · < bn as desired.
All of the above computations require a value for σ2, which
we identify through a grid search of candidate values. For each
candidate value, a series of small simulation studies should be
performed to assess the performance of the algorithm when
the prior means are correctly specified as well as situations
when the prior means are too high or too low. An appropri-
ate value of σ2 is one that is small enough so that the prior is
sufficiently informative when there are limited data at the be-
ginning of a trial, but large enough so that the prior becomes
sufficiently noninformative when there are enough data later
in the trial. Although each trial setting will require fine-tuning
of σ2, we have found in our settings that values of σ2 in the
interval [5, 10] are often sufficient. Note that because equa-
tions (1) and (2) are additive in both doses, the variance of
pjk necessarily grows with aj and bk . We examined situations
in which we scaled σ2 by aj or bk as an attempt to keep the
variance stable among all combinations. However, we found
that the algorithm did no better with this variance stabi-
lization than it did without it. Furthermore, the nonconstant
variance model has practical suitability, as it is plausible that
there is more certainty about prior values of pjk for combi-
nations of lower dose values than for combinations of higher
dose values.
4. Trial Design and Conduct
Before the trial begins enrolling subjects, the investigators
should first specify: (a) the (m + n − 1) prior probabilities of
DLT for combinations containing the lowest dose of Agent A
and/or Agent B, and (b) the targeted probability of DLT, p∗.
From this information, the study statistician can determine
values for all hyperparameters and effective doses as described
in Section 3. At this point, subject i = 1 can be enrolled and
assigned to combination (j1, k1) = (1, 1). In order to determine
the dose assignment (ji , ki ) for each subject i = 2, 3, . . . , N ,
the conduct of the trial proceeds as follows:
(1) Compute a 95% confidence interval for the overall DLT
rate among all combinations using the cumulative num-
ber of observed DLTs for subjects 1, 2, . . . , (i − 1).
(2) If the lower bound of the confidence interval from step
(1) is greater than p∗, terminate the trial.
(3) If the lower bound of the confidence interval from step
(1) is no more than p∗:
(a) Use the outcomes and assignments of subjects
1, 2, . . . , (i − 1) to determine the posterior distri-
bution of each pjk , with posterior mean p̄j k , as de-
scribed in Section 2;
(b) Define the set S = {(j, k) : ji−1 − 1 ≤ j ≤ ji−1 +
1, ki−1 − 1 ≤ k ≤ ki−1 + 1} that contains combina-
tions that are within one dose level of the corre-
sponding doses in the combination assigned to the
most recently enrolled subject;
(c) Identify the combination (j∗, k∗) in S as the one
with smallest djk = |p̄j k − p∗|;
(d) Assign subject i to (ji , ki ) = (j∗, k∗).
(4) If all N subjects have been enrolled and followed, re-
peat steps (3a)–(3c) with the data of all N subjects to
identify the MTC.
Recall that our design enrolls all subjects in a single stage,
rather than in two stages. Although some authors feel that the
first stage is needed to limit the influence of the prior when
little data have been collected, we feel that a well-designed
sensitivity analysis of σ2 prior to inception of the study will
serve to limit the influence of the prior in the early portion of
the study. Also, step (1) in our trial is completely data-driven
and allows for early termination of the study without input
from the prior distribution. We did examine a stopping rule
based upon the percentage of the posterior distributions of
each pjk above p∗ but found this stopping rule did not lead
to study termination often enough if all of the combinations
were overly toxic. The width of the confidence interval used
in step (1) can also be modified to increase or decrease the
probability of early termination.
Like most dose-finding studies, we enforce a “do not skip”
rule in step (3b) of our conduct; however, we apply this rule
to escalation as well as to de-escalation. Specifically, subject
i must be assigned to a combination that is in a “close neigh-
borhood,” as defined in step (3b), of the combination assigned
to subject (i − 1). By doing so, we hope to limit the number
of patients exposed to overly toxic combinations while still al-
lowing the algorithm to fully search the entire grid of possible
combinations. We examined putting no limit on de-escalation
(as is done in most single-agent studies) but found that our
algorithm then had difficulty identifying the optimal combi-
nation if it existed at high-dose combinations of both agents,
as a single DLT had large influence on the posterior distribu-
tions of the pjk .
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Our approach allows for simultaneous dose escalations of
both agents, which may appear to be overly aggressive and
increase the likelihood of exposing too many subjects to overly
toxic combinations. However, we cite the work of Wang and
Ivanova (2005), as well as that of Braun et al. (2007) in the
setting of simultaneous dose/schedule finding, who found es-
calation of both dimensions simultaneously does not lead to
an increased observed toxicity rate. Furthermore, allowing si-
multaneous escalations in both doses increases the ability of
the algorithm to fully explore all combinations in a neighbor-
hood of the actual MTC when the MTC is a combination
of high doses for both agents. Note that escalation could be
slowed by requiring that a cohort of M patients be assigned
to the same combination before escalation can be considered.
However, we have found that using M = 1 is sufficient for
limiting escalation and using values of M > 1 will treat too
many subjects at suboptimal combinations and unnecessarily
increase the overall sample size of the study when the MTC
is a combination of high doses of both agents.
5. Numerical Studies
5.1 Operating Characteristics
We examine the performance of our algorithm in six scenarios
(A through F) for a hypothetical clinical trial of N = 35 sub-
jects, where the sample size was selected for feasibility yet also
satisfactory operating characteristics across all six scenarios.
We also examined sample sizes of N = 40 and N = 50 in small
simulation studies and found little improvement in the oper-
ating characteristics seen with N = 35. The trial is designed
to determine which of four doses of Agent A (m = 4) and
which of four doses of Agent B (n = 4), when given in com-
bination, lead to a DLT rate close to p∗ = 0.20. The actual
DLT rates for each combination under each scenario are dis-
played in the first four columns of values in Table 1. Scenario
A has an abundance of tolerable combinations at higher dose
levels of one or both agents, while Scenario B has all combi-
nations with DLT probabilities under the target p∗. Scenario
C has very few tolerable combinations and Scenario D has
no tolerable combinations. Scenarios E and F are settings in
which the probability of DLT increases little with dose in-
creases of one agent yet increases steeply with dose increases
of the other agent, increasing the difficulty of identifying a
single best choice for the MTC.
The a priori rates of DLT elicited from investigators are
equal to the actual DLT rates in Scenario A. Based upon
these values, the investigators believe combination (2, 3) is
optimal as it has a DLT rate equal to that desired. Using
the methods described in Section 3, we produce the effective
dose values a1 = 0.000, a2 = 0.058, a3 = 0.094, and a4 = 0.120
for Agent A and b1 = 0.000, b2 = 0.078, b3 = 0.120, and b4 =
0.151 for Agent B and hyperparameter values σ2 = 10, μ =
{3.69, 6.32, 6.32}, and ω = {6.87, 6.32, 6.32}. The value σ2 =
10 was selected from a grid search of values 1, 2, . . . 12. Specif-
ically, we performed small simulation studies of 100 replica-
tions with each possible value of σ2 in each of the six scenarios
and found that σ2 = 10 led to a prior distribution that was
sufficiently informative during the early portion of a study and
also allowed the data to dominate during the latter portion
of a study across all scenarios.
We ran 1000 simulations of our algorithm under each sce-
nario; the performance of our algorithm is summarized in
the final eight columns of Table 1. The first four of the
eight columns display the percentage of simulations in which
each combination was identified as the MTC at the end
of the study, and the last four of the eight columns dis-
play the average percentage of 35 subjects among all simu-
lations that were assigned to each combination. All simula-
tions were done in the statistical package R. A total of 2000
draws from the posterior distributions of each αjk and βjk
were generated with the MCMC machinery supplied in the
JAGS (Just Another Gibbs Sampler) library. User-friendly R
code is available for applying our methods to both simulation
studies and actual trials; the code can be downloaded from
www.sph.umich.edu/∼tombraun/software.html.
As we discuss the results, we note that although we wish to
target combinations whose DLT probability is 0.20, selecting
combinations whose DLT probabilities are within 10 points
of 0.20 (which we call the “10-point window”) still indicates
satisfactory performance of our algorithm, as: (1) a sample
size of 35 subjects is insufficient for discrimination between
DLT rates in the interval [0.10, 0.30], and (2) in most clini-
cal applications, the desired DLT rate is often a rough guess
and finding combinations with DLT rates close to the target
rate selected by the investigator will still prove to be of inter-
est to the investigator. A narrower window could certainly be
used. However, a level of performance with this narrower win-
dow equivalent to that we observed with our 10-point window
would directly increase the sample size chosen for the study.
In Scenario A our algorithm selects combinations within
the 10-point window as the MTC in 89% of simulations and
assigns an average of 76% of subjects to those combinations.
Furthermore, within the 10-point window, our algorithm is
more likely to select combinations and assign patients to those
combinations with DLT rates within four points of 0.20. In
Scenario B, we see combinations including doses 3 and 4 of
either agent are selected as the MTC and assigned to sub-
jects more often than they were in Scenario A, reflecting the
increased safety of those combinations that would be demon-
strated in the data. Conversely in Scenario C, we see combi-
nations including doses 1 and 2 of either agent are selected as
the MTC and assigned to subjects more often than they were
in Scenario A, reflecting the increased toxicity of those com-
binations that would be demonstrated in the data. Scenarios
A, B, and C demonstrate that the prior we selected for θ and
φ is sufficiently noninformative so as to allow the algorithm
to “move with the data.” Early termination occurred in 1%,
0%, and 16% of simulations in Scenarios A–C, respectively;
the increased early termination rate in Scenario C is due to a
majority of combinations being unacceptably toxic.
In Scenario D, where no combinations were tolerable, we
see that an MTC was very rarely identified, with only 5%
of simulations fully enrolling 35 patients and identifying the
MTC at combination (1, 1), which was also the combination
most frequently assigned to subjects. From the results pre-
sented in Table 1 for scenarios E and F, we see that our algo-
rithm is able to adjust for distinctly differential dose-toxicity
patterns of the two agents and still identifies the MTC at
combinations in a neighborhood of the true MTC and assigns
a preponderance of subjects to those combinations. However,
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Table 1
Summary of true DLT probabilities and simulation results for Scenarios A through F. All probabilities and percentages are
multiplied by 100. Values in boldface correspond to combinations with a true DLT probability within 10 points of the target
probability p∗ = 0.20. In all six settings, the prior probabilities of DLT for each combination equal the actual probabilities of DLT
in Scenario A, leading to hyperparameter values μ = {3.69, 6.32, 6.32}, ω = {6.87, 6.32, 6.32}, and σ2 = 10.
Dose of agent A
True DLT Percentage of simulations Mean percentage of
probability selected as MTC subjects assignedDose of
Scenario agent B 1 2 3 4 1 2 3 4 1 2 3 4
A 1 4 8 12 16 0 2 2 4 6 3 3 2
2 10 14 18 22 3 9 11 7 4 10 8 4
3 16 20 24 28 6 12 13 7 5 8 13 6
4 22 26 30 34 5 6 6 6 3 4 6 15
B 1 2 4 6 8 0 0 0 0 4 1 1 1
2 5 7 9 11 0 1 2 2 1 5 3 2
3 8 10 12 14 1 2 7 8 1 3 10 6
4 11 13 15 17 1 2 11 61 1 2 7 52
C 1 10 20 30 40 15 27 9 3 23 21 8 3
2 25 35 45 55 20 3 0 0 14 9 2 1
3 40 50 60 70 6 0 0 0 6 2 3 0
4 55 65 75 85 0 0 0 0 1 0 0 1
D 1 44 48 52 56 5 0 0 0 27 4 1 0
2 50 54 58 62 0 0 0 0 2 3 0 0
3 56 60 64 68 0 0 0 0 1 0 1 0
4 62 66 70 74 0 0 0 0 0 0 0 0
E 1 8 18 28 38 2 9 6 5 10 8 5 3
2 9 19 29 39 8 11 11 3 6 12 7 3
3 10 20 30 40 6 12 6 2 5 8 9 3
4 11 21 31 41 5 4 3 2 4 3 3 8
F 1 12 13 14 15 6 8 9 7 14 9 7 5
2 16 18 20 22 16 14 6 1 11 14 7 2
3 44 45 46 47 11 4 1 0 8 5 5 1
4 50 52 54 55 2 0 0 0 2 1 1 3
we do see in Scenario F that the algorithm selects combina-
tions with dose 3 of Agent B more often than desired. This
result is due to the dramatic increase in DLT rates between
doses 2 and 3 of Agent B that does not fit our assumed model
in equations (1) and (2). Our model underestimates the tox-
icity probabilities of combinations including doses 3 and 4
of Agent B, making them more likely to be identified as the
MTC and assigned to subjects more than desired. Nonethe-
less, the dose-toxicity pattern of Agent B in Scenario F would
challenge any parametric model applied to this setting. Early
termination occurred in 11% and 12% of simulations in Sce-
narios E and F, respectively. One may argue that since there
was at least one optimal combination in Scenarios C, E, and
F, it is not desirable to observe early termination in those
scenarios. However, in order to have a design that stops early
with high probability when all combinations are overly toxic,
we have to allow for some early termination when very few
optimal combinations exist. As stated earlier, we examined
stopping rules based upon the posterior distributions of the
parameters rather than the actual number of observed DLTs,
but found those stopping rules were unable to stop the study
soon enough when all combinations were overly toxic unless
the prior was skewed toward having all combinations being
overly toxic.
As a final summary of the performance of our algorithm,
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Figure 1. Pattern of dose assignments.
across all 1000 simulations in terms of the actual DLT rates
of the combinations. For example, in Scenario A, if two sub-
jects were assigned to combinations (1, 2) and (2, 1), their
respective assignments were given values of 0.10 and 0.08. All
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Table 2
Comparison of proposed design to CRM and design of Wang and Ivanova (2005). All percentages are multiplied by 100. Values
in boldface correspond to combinations with a true DLT probability within 10 points of the target probability p∗ = 0.20.
Dose of agent A
Braun CRM Wang and IvanovaDose of
Scenario agent B 1 2 3 4 1 2 3 4 1 2 3 4
Percentage of simulations selected as MTC
A 1 0 2 2 4 0 2 7 6 0 0 0 3
2 3 9 11 7 5 11 13 4 0 0 2 8
3 6 12 13 7 5 11 10 6 7 7 21 15
4 5 6 6 6 5 7 4 4 2 5 11 16
B 1 0 0 0 0 0 0 1 1 0 0 0 0
2 0 1 2 2 0 1 3 2 0 0 0 0
3 1 2 7 8 1 4 7 8 0 0 1 4
4 1 2 11 61 2 8 12 50 0 2 10 82
E 1 2 9 6 5 8 15 12 4 0 0 8 6
2 8 11 11 3 17 10 6 3 0 1 14 8
3 6 12 6 2 4 6 4 2 6 11 19 7
4 5 4 3 2 2 4 1 1 2 6 6 4
Mean percentage of subjects sssigned
A 1 6 3 3 2 7 9 9 6 6 5 5 9
2 4 10 8 4 8 10 9 4 2 4 3 5
3 5 8 13 6 6 8 5 3 4 4 10 8
4 3 4 6 15 5 4 3 3 1 5 9 20
B 1 4 1 1 1 4 4 5 4 6 5 5 11
2 1 5 3 2 4 5 5 4 1 3 2 2
3 1 3 10 6 4 6 6 6 1 1 2 5
4 1 2 7 52 4 6 9 24 0 2 5 50
E 1 10 8 5 3 18 17 11 4 6 5 5 5
2 6 12 7 3 12 8 5 2 4 5 8 6
3 5 8 9 3 4 4 3 2 5 7 11 6
4 4 3 3 8 3 3 2 1 2 7 8 8
subjects not receiving an assignment due to early termination
were given a value of 0.00. The hope is that as more and more
subjects are enrolled, the average combination assigned to the
final subject has a DLT rate close to the target of p∗ = 0.20
(the horizontal line in Figure 1). In all scenarios except Sce-
nario D, we see that the final subject is assigned on average
to a combination whose DLT rate is quite close to the tar-
geted DLT rate. The pattern for Scenario D reflects the fact
that later subjects tended to receive no assignment and the
average DLT rate tends toward 0.00.
5.2 Comparison to Alternate Methods
We also compared the performance of our approach to the
performance of the CRM and the approach of Wang and
Ivanova (2005) in all six scenarios. Table 2 displays results
for Scenarios A, B, and E; Scenarios C, D, and F are omit-
ted, as the results for each were similar to the results for one
of the presented scenarios. For the approach of Wang and
Ivanova, we selected Agent A as “dose 1” and applied the
model, prior distributions, and study design exactly as de-
scribed in their manuscript, except that in the second stage,
we enrolled patients in cohorts of size one rather than three.
For the CRM, we ordered the 16 combinations by their prior
DLT rates (the actual DLT rates in Scenario A). For these 16
“doses,” d̃ ,  = 1, 2, . . . 16, we used the model p = d̃
ζ
 , where
p is the probability of DLT for “dose”  and ζ had an expo-
nential distribution with mean one. Note that combinations
(1, 3) and (4, 1) had equal prior DLT rates and thus equal
ordering for the CRM. If those combinations were selected
by the CRM as the MTC, the algorithm was programmed to
choose one of the combinations with equal probability as the
assignment for the next subject. The same approach was used
with combinations (4, 2) and (1, 4).
In Scenarios A and B, we see fairly comparable performance
between our proposed method and the CRM. However, in sce-
nario A, the CRM assigns 80% of subjects to combinations
in the 10-point window, compared to 76% for our method,
and in Scenario B, our method selects and assigns combina-
tion (4, 4) much more often than the CRM does. The method
of Wang and Ivanova (2005) has noticeably poorer perfor-
mance in Scenario A, tending to select and assign combina-
tions that include dose 3 or 4 of both agents. This result is
likely due to the prior distribution for each parameter sug-
gested by the authors (exponential with mean one). It is pos-
sible that changing the exponential distribution to a gamma
distribution with mean one but flexible variance would allow
for a less-informative prior distribution and move the algo-
rithm away from the higher dose combinations. This pref-
erence for higher dose combinations also leads to improved
performance in Scenario B over our method and the CRM.
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Table 3
Assessing the impact of the chosen prior distribution on the operating characteristics presented for Scenario A in Table 1. All
percentages are multiplied by 100. All combinations have a true DLT probability within 10 points of the target probability
p∗ = 0.20, except combinations (1, 1), (2, 1), and (4, 4).
Dose of agent A
Percentage of simulations Mean % of
Prior parameters selected as MTC subjects assignedDose of
Scenario μ ω σ2 agent B 1 2 3 4 1 2 3 4
A1 4.79 6.78 10 1 2 2 4 3 8 3 3 2
6.32 6.32 2 1 5 10 25 2 8 7 18
6.32 6.32 3 16 8 7 2 9 7 10 3
4 2 4 3 5 1 3 3 12
A2 3.00 6.98 10 1 0 1 2 3 6 3 3 2
6.32 6.32 2 2 6 8 6 3 10 7 4
6.32 6.32 3 5 9 10 5 5 8 12 6
4 4 5 6 5 3 4 6 18
A3 4.79 6.78 5 1 1 3 4 3 8 3 3 2
4.47 4.47 2 3 7 9 23 2 9 8 17
4.47 4.47 3 16 8 6 1 10 7 10 2
4 2 4 4 4 1 3 4 11
A4 3.00 6.98 5 1 0 2 4 2 5 3 3 2
4.47 4.47 2 3 9 11 7 4 10 8 4
4.47 4.47 3 5 13 12 6 5 9 13 5
4 6 6 5 7 3 4 6 16
A5 4.79 6.78 15 1 2 2 3 4 7 3 3 2
7.75 7.75 2 2 5 9 24 2 8 7 17
7.75 7.75 3 17 8 8 2 10 7 11 3
4 2 4 4 5 1 3 4 13
A6 3.00 6.98 15 1 0 2 2 3 6 3 3 2
7.75 7.75 2 3 11 8 7 3 10 8 4
7.75 7.75 3 5 12 14 8 4 8 13 6
4 6 6 7 6 3 4 6 18
Scenario E demonstrates the primary limitation of using
the CRM, which was designed for studies of a single agent,
rather than a design specifically created to examine combina-
tions of two agents. The forced ordering of the combinations
reflected in the prior DLT rates is drastically different from
the true ordering of the combinations. Thus, the CRM tends
to focus upon combinations that include the lowest two doses
of either agent, as opposed to our method, which is able to
more often select and assign combinations that include the
middle two doses of either agent.
5.3 Assessing Influence of Prior
In Table 3, we present results for Scenario A using six prior
distributions with means and/or variance different from that
used for the simulations presented in Table 1. The prior DLT
rates used in Scenarios A1, A3, and A5 were the actual DLT
rates of Scenario F shown in Table 1 and the prior DLT rates
used in Scenarios A2, A4, and A6 were the actual DLT rates of
Scenario B. The prior variance in Scenarios A1 and A2 equals
that for the simulations of Section 5.1 (σ2 = 10), while Sce-
narios A3 and A4 have a smaller prior variance (σ2 = 5) and
Scenarios A5 and A6 have a larger prior variance (σ2 = 15).
By comparing the results in Table 3 to the results of Scenario
A in Table 1, we see there are slight variations in which com-
binations are selected as the MTC. For example, in Scenarios
A1, A3, and A5, combination (4, 2) is selected as the MTC
more often than it was before. However, patient assignments
and the algorithm’s ability to identify combinations within
the 10-point window as the MTC are generally unaffected by
the choice of prior.
6. Conclusion
Our article has proposed a Bayesian hierarchical design for
identifying doses of two agents with optimal DLT rates when
given in combination. The important aspects of our design in-
clude the sequential enrollment of subjects in a single stage,
an explicit procedure for developing model parameter prior
distributions from a set of DLT rates elicited from investiga-
tors, and a design that formally accommodates patient hetero-
geneity. Future planned extensions of our model include the
incorporation of weights into our likelihood to allow decision
making with partial follow-up of currently enrolled subjects,
thus allowing subjects to be enrolled as soon as they are eligi-
ble and shortening the duration of the trial. We also want to
generalize our model to accommodate the actual administra-
tion times of the two agents, as many dual-agent therapies do
not administer both agents simultaneously and the length of
delay of the second agent may be important when assessing
the DLT rate of the combination.
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